Latest news | Bottneuro | Digital solutions for Alzheimer’s patients

Latest news

Bottneuro at the BOOM Summit 2024
Featured

Bottneuro at the BOOM Summit 2024

Bottneuro is excited for two healthtech-filled days at BOOM Summit 2024 in Basel, Switzerland.
10 April, 2024
Read more
Bottneuro at the Mental & Brain Tech Tour 2024
Featured
Bottneuro at the Mental & Brain Tech Tour 2024
European patent granted
Featured
European patent granted

Featured news

Bottneuro at the BOOM Summit 2024
Featured
Bottneuro at the BOOM Summit 2024
10 April, 2024
Bottneuro at the Mental & Brain Tech Tour 2024
Featured
Bottneuro at the Mental & Brain Tech Tour 2024
05 April, 2024
European patent granted
Featured
European patent granted
03 April, 2024
Bottneuro's Miamind Neurostimulator Spotlighted in Uni Basel Article
Featured
Bottneuro's Miamind Neurostimulator Spotlighted in Uni Basel Article
02 April, 2024
Bottneuro at the LSIUSA24
Featured
Bottneuro at the LSIUSA24
18 March, 2024
MINDSTIM study has successfully concluded
Featured
MINDSTIM study has successfully concluded
15 March, 2024
Start of the intervention phase of the MINDSTIM study
Featured
Start of the intervention phase of the MINDSTIM study
04 March, 2024
Bottneuro publishes Whitepaper
Featured
Bottneuro publishes Whitepaper
23 January, 2024
The MINDSTIM clinical trial officially started!
Featured
The MINDSTIM clinical trial officially started!
04 January, 2024
Miamind® Neurostimulator officially registered with Swissmedic and MHRA
Featured
Miamind® Neurostimulator officially registered with Swissmedic and MHRA
24 November, 2023
Bottneuro at MEDICA 2023
Featured
Bottneuro at MEDICA 2023
13 November, 2023
Bottneuro at the Biosensors for Medical Wearables Conference
Featured
Bottneuro at the Biosensors for Medical Wearables Conference
23 October, 2023
Bottneuro at the UK Medtech Mission for Swiss Start-ups
Featured
Bottneuro at the UK Medtech Mission for Swiss Start-ups
16 October, 2023
Bottneuro at the Swiss Medtech Expo Symposium
Featured
Bottneuro at the Swiss Medtech Expo Symposium
12 September, 2023
Miamind® Neurostimulator Achieves Official Certification from DEKRA
Featured
Miamind® Neurostimulator Achieves Official Certification from DEKRA
01 September, 2023
Prof. Christoph Michel joined as an Advisor
Featured
Prof. Christoph Michel joined as an Advisor
01 July, 2023
Prof. Dr. Emiliano Santarnecchi joined as an Advisor
Featured
Prof. Dr. Emiliano Santarnecchi joined as an Advisor
01 May, 2023
Followup to Bottneuro's collaboration with Samsung!
Featured
Followup to Bottneuro's collaboration with Samsung!
13 March, 2023
Partnership Samsung & Bottneuro
Featured
Partnership Samsung & Bottneuro
15 February, 2023
Supporter of the Dementia Conference in Bern 2023
Featured
Supporter of the Dementia Conference in Bern 2023
01 February, 2023
Winner of IMD Startup Competition in 2022/2023
Featured
Winner of IMD Startup Competition in 2022/2023
15 December, 2022
Approval on UpLink
Featured
Approval on UpLink
11 July, 2022
Latest headset design
Featured
Latest headset design
08 June, 2022
Bottneuro welcomes a new team member
Featured
Bottneuro welcomes a new team member
02 June, 2022
Bottneuro welcomes a new team member
Featured
Bottneuro welcomes a new team member
05 May, 2022
Bottneuro welcomes two new team members
Featured
Bottneuro welcomes two new team members
22 April, 2022
Supporter at the Dementia Conference in Bern 2022
Featured
Supporter at the Dementia Conference in Bern 2022
29 March, 2022
Bottneuro moves to a new location
Featured
Bottneuro moves to a new location
24 March, 2022
Bottneuro wins CHF 150,000 to advance diagnosis and digital therapies for Alzheimer’s disease
Featured
Bottneuro wins CHF 150,000 to advance diagnosis and digital therapies for Alzheimer’s disease
17 December, 2021
Switzerland advances personalized Alzheimer’s therapy
Featured
Switzerland advances personalized Alzheimer’s therapy
29 November, 2021
BottNeuro advancing personalized alzheimer’s therapy
Featured
BottNeuro advancing personalized alzheimer’s therapy
04 November, 2021
Alzheimer: Schweizer Firma plant Diagnose-Zentren
Featured
Alzheimer: Schweizer Firma plant Diagnose-Zentren
02 November, 2021
Bottneuro passes 2nd stage of Venture Kick: CHF 40'000.-
Featured
Bottneuro passes 2nd stage of Venture Kick: CHF 40'000.-
08 July, 2021
BottNeuro passes 1st stage of Venture Kick: CHF 10'000.-
Featured
BottNeuro passes 1st stage of Venture Kick: CHF 10'000.-
23 March, 2021
BottNeuro advancing personalized Alzheimer’s therapy
Featured
BottNeuro advancing personalized Alzheimer’s therapy
11 February, 2021
Gebert Rüf supports NENI project with CHF 300'000.-
Featured
Gebert Rüf supports NENI project with CHF 300'000.-
01 August, 2019

Social Media

LinkedIn
Twitter
We use cookies to personalize content and to analyze our traffic. Please decide if you are willing to accept cookies from our website.